The European Medicines Agency has started evaluating the COVID-19 vaccine by the Chinese company Sinovac. She added that preliminary results from animal and human studies suggest that the vaccine triggers an immune response against the coronavirus.
As EMA said in a statement, the decision to initiate the evaluation is based on preliminary results from laboratory and clinical studies that suggest that Sinovac induces the production of antibodies against the SARS-CoV-2 virus and may help protect against COVID-19.
The CoronaVac vaccine by Sinovac has so far only been approved in the Chinese market without restrictions. At the same time, however, Beijing sent millions of its doses to many countries in Southeast Asia, Latin America and Africa. Ukraine and Turkey also signed large contracts for them.
Main photo source: WEN TAN / EPA / PAP